Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review.
Curr Drug Saf · 2025
Last updated 2026-05-28A review of reports from regulatory agencies and studies found cases of suicidal thoughts and self-injurious behavior linked to GLP-1 receptor agonists, which are medications used for type 2 diabetes and weight loss. The review highlights these serious side effects and advises healthcare professionals to be aware of them, while also warning against misuse of these drugs for weight loss without medical supervision.
AI summary of the abstract below.
| Journal | Curr Drug Saf, 2025 |
|---|---|
| Citations | 1 |
| Molecules | — |
| Conditions studied | Depression |
Abstract
GLP-1 receptor agonists mimic the actions of GLP-1 and are used to manage type 2 diabetes and help with weight loss. In recent times, antidiabetic GLP-1 receptor agonists have been misused widely for weight loss. This review article focuses on some serious side effects of GLP-1 receptor agonists, notified by different regulatory agencies. We searched the literature in online databases such as Medline/Pubmed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of Science, Embase, and reference lists to identify publications relevant to the serious side effects associated with the use of GLP-1 receptor agonists. Various pharmacovigilance analyses and notifications from different regulatory agencies have documented the occurrence of suicidal thoughts and self-injurious behavior associated with the use of GLP-1 receptor agonists. Healthcare professionals should be aware of GLP-1 receptor agonistsassociated suicidal thoughts and self-injurious behavior. Patients should not misuse/abuse antidiabetic GLP-1 receptor agonists and should consult their physician before using any GLP-1 receptor agonists for weight loss.
Verbatim abstract via PubMed 38766830 ↗